Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Completed 3Withdrawn 2Terminated 1

Sponsor Class

INDUSTRY 13OTHER 3NETWORK 1

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 1NET 1Gastrointestinal 1Endocrine 1

Conditions

Pleural Effusion 1Pancreatic Neoplasms 1Neuroendocrine Tumors 1Lung Neoplasms 1Insulin-Like Growth Factor I, Resistance To 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Cyclophosphamide 956Radiotherapy 847Cisplatin 757Gemcitabine 657Carboplatin 603Docetaxel 598Paclitaxel 585Bevacizumab 580Fluorouracil 504Oxaliplatin 458Rituximab 453Surveys and Questionnaires 449Capecitabine 440Dexamethasone 428Doxorubicin 424Etoposide 411Irinotecan 389Cytarabine 376Filgrastim 369pembrolizumab 330Leucovorin 305Nivolumab 296fludarabine phosphate 294Melphalan 288Magnetic Resonance Spectroscopy 281Peripheral Blood Stem Cell Transplantation 279Blood Specimen Collection 279Methotrexate 276Lenalidomide 276Cetuximab 270

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Completed × OTHER × dalotuzumab × Clear all
NCT00769483 2020-09-03

MK-0646 and Gemcitabine +/- Erlotinib for Patients With Advanced Pancreatic Cancer

M.D. Anderson Cancer Center

Phase 1/2 Completed
81 enrolled 19 charts
Gastrointestinal

Pancreatic Neoplasms

NCT00610129 2015-11-20

Clinical and Translational Study of MK-0646 in Patients With Metastatic Neuroendocrine Tumors (NET)

Memorial Sloan Kettering Cancer Center

Phase 2 Completed
25 enrolled 6 charts
EndocrineNET

Neuroendocrine Tumors

NCT00799240 2014-11-07

IMPACT

University of Kansas Medical Center

Phase 2 Completed
27 enrolled
Thoracic

Insulin-Like Growth Factor I, Resistance To, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Pleural Effusion

Data powered by HemOnc (CC BY 4.0) Colophon âš¡